Perikabiven
- Generic Name: amino acids, electrolytes, dextrose and lipid injectable emulsion for intravenous use
- Brand Name: Perikabiven
Perikabiven (Amino Acids, Electrolytes, Dextrose and Lipid Injectable Emulsion for Intravenous Use) side effects drug center
- Related Drugs
- nausea
- fever
- high blood pressure
- vomiting
- decreased hemoglobin
- decreased total protein
- low blood potassium (hypokalemia)
- increased gamma glutamyltransferase
- high blood sugar, and
- itching
- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
- Infections [see WARNINGS AND PRECAUTIONS]
- Fat Overload Syndrome [see WARNINGS AND PRECAUTIONS]
- Refeeding Syndrome [see WARNINGS AND PRECAUTIONS]
- Diabetes/Hyperglycemia [see WARNINGS AND PRECAUTIONS]
- Thrombophlebitis [see WARNINGS AND PRECAUTIONS]
- Hepatobiliary Disorders [see WARNINGS AND PRECAUTIONS]
- Electrolyte Imbalance and Fluid Overload in Renal Impairment [see WARNINGS AND PRECAUTIONS]
- Hypertriglyceridemia [see WARNINGS AND PRECAUTIONS]
- Aluminum Toxicity [see WARNINGS AND PRECAUTIONS]
- Gastrointestinal disorders: abdominal distension, abdominal pain
- General disorders and administration site conditions: chest tightness
- Hepatobiliary disorders: cholestasis
- Immune system disorders: allergic reaction, anaphylaxis
- Infections and infestations: infection
- Vascular disorders: flushed face
What Is Perikabiven?
Perikabiven (amino acids, electrolytes, dextrose and lipid) Injectable Emulsion is a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Perikabiven may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients.
What Are Side Effects of Perikabiven?
Common side effects of Perikabiven include:
Dosage for Perikabiven
The dosage of Perikabiven is individualized based on the patient's clinical condition, body weight and nutritional/fluid requirements, as well as additional energy given orally/enterally to the patient.
What Drugs, Substances, or Supplements Interact with Perikabiven?
Perikabiven may interact with coumarin or coumarin derivatives. Tell your doctor all medications and supplements you use.
Perikabiven During Pregnancy and Breastfeeding
During pregnancy, Perikabiven should be administered only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Perikabiven (amino acids, electrolytes, dextrose and lipid) Injectable Emulsion Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
SIDE EFFECTS
The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The clinical data described for PERIKABIVEN® reflects exposure in 93 patients exposed for 5 to 7 days in 4 active-controlled trials. The pooled population exposed to PERIKABIVEN® was 18 to 87 years old, 48% female, 73% Caucasian. The enrolled patients had varied underlying conditions such as gastrointestinal disorders (55%), vascular disorders (30%), metabolism and nutrition disorders (28%), respiratory, thoracic, and mediastinal disorders (22%), and psychiatric disorders (20%). Most patients received peripheral intravenous infusion doses of ≥80% of their target mean daily exposure.
Adverse reactions occurring in at least 2% of patients who received PERIKABIVEN® are shown in Table 3.
Table 3: Adverse Reactions in >2% of Patients Treated with PERIKABIVEN
| Adverse reaction | PERIKABIVEN ® N=93 (%) |
| Hyperglycemia* | 5 (5) |
| Hypokalemia | 4 (4) |
| Pyrexia | 4 (4) |
| Blood triglycerides increased | 3 (3) |
| Phlebitis | 2 (2) |
| Nausea | 2 (2) |
| Pruritus | 2 (2) |
| Gamma-glutamyltransferase increased | 2 (2) |
| Blood alkaline phosphatase increased | 2 (2) |
| Alanine aminotransferase increased | 2 (2) |
| Blood glucose increased* | 2 (2) |
| C-reactive protein increased | 2 (2) |
| Blood urea increased | 2 (2) |
| Hypoalbuminemia | 2 (2) |
| * Terms as reported in clinical studies | |
Less common adverse reactions in ≤1% of patients who received PERIKABIVEN® were hyperkalemia, hypomagnesaemia, hypernatremia, tachycardia, hypertension, thrombophlebitis, vomiting, jaundice, rash and increased blood bilirubin.
Post-Marketing Experience
The following additional adverse reactions have been identified during post-approval use of PERIKABIVEN in countries where it is registered. Because these reactions are reported voluntarily post-approval from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure.
Read the entire FDA prescribing information for Perikabiven (Amino Acids, Electrolytes, Dextrose and Lipid Injectable Emulsion for Intravenous Use)
© Perikabiven Patient Information is supplied by Cerner Multum, Inc. and Perikabiven Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.